Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients

NCT03281824 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

BIOLOGICAL: ALT-P7 (HM2-MMAE)

Sponsor

Alteogen, Inc.